Stifel downgraded Nyxoah (NYXH) to Hold from Buy with a price target of $5, down from $8. The downgrade is not specific to the Q1 earnings announcement due tomorrow after market close, but a belief that hypoglossal nerve stimulation reimbursement challenges persist for the balance of the year, the analyst tells investors. The firm would \"only want one horse in a challenging HGNS market\" and would select Inspire Medical (INSP) over Nyxoah, says the analyst, who keeps a Buy rating and $65 price target on Inspire shares.
